Patents by Inventor Douglas Frantz

Douglas Frantz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140364467
    Abstract: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 11, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jay Schneider, Jenny Hsieh, Douglas Frantz, Steven L. McKnight, Joseph M. Ready
  • Patent number: 8778940
    Abstract: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: July 15, 2014
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Jay Schneider, Jenny Hsieh, Douglas Frantz, Steven L. McKnight, Joseph M. Ready
  • Patent number: 8686012
    Abstract: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: April 1, 2014
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Eric N. Olson, Douglas Frantz, Jenny Hsieh, Steven L. McKnight, Jay Schneider
  • Patent number: 8660855
    Abstract: Embodiments of the present invention relate to methods and apparatuses serving to provide assurance that healthcare providers will receive payment for services rendered. In one embodiment, a payment card (or other portable consumer device) provides an extended authorization hold period (for example up to 21 days). This hold period allows the healthcare provider to request authorization for payment from the patient's credit, debit, FSA, HRA, or HSA payment card, submit the insurance claim, and then upon receipt of a health insurance carrier's Explanation of Benefits (EOB) within the hold period, submit for settlement only that amount actually due from the patient. In accordance with an alternative embodiment, pending receipt of the EOB from the insurer, the healthcare provider flags a transaction in a point-of-sale (POS) terminal device or server for storage and delayed submittal over an electronic payment network.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: February 25, 2014
    Assignee: VISA U.S.A. Inc.
    Inventors: Stacy Pourfallah, Janet Pruitt, Douglas Frantz, Roxanna Kayoumi
  • Publication number: 20130143885
    Abstract: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.
    Type: Application
    Filed: June 4, 2012
    Publication date: June 6, 2013
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jay Schneider, Jenny Hsieh, Douglas Frantz, Steven L. McKnight, Joseph M. Ready
  • Patent number: 8318951
    Abstract: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: November 27, 2012
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Eric N. Olson, Douglas Frantz, Jenny Hsieh, Steven L. McKnight, Jay Schneider
  • Patent number: 8193225
    Abstract: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The compounds are isoxazole amides and derivatives thereof. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: June 5, 2012
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Jay Schneider, Jenny Hsieh, Douglas Frantz, Steven L. McKnight, Joseph M. Ready
  • Publication number: 20120029200
    Abstract: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.
    Type: Application
    Filed: May 26, 2011
    Publication date: February 2, 2012
    Inventors: Eric N. Olson, Douglas Frantz, Jenny Hsieh, Steven L. McKnight, Jay Schneider
  • Patent number: 7981935
    Abstract: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: July 19, 2011
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Eric Olson, Douglas Frantz, Jenny Hsieh, Steven L. McKnight, Jay Schneider
  • Publication number: 20090076103
    Abstract: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.
    Type: Application
    Filed: July 31, 2008
    Publication date: March 19, 2009
    Inventors: Eric Olson, Douglas Frantz, Jenny Hsieh, Steven L. McKnight, Jay Schneider
  • Publication number: 20090036451
    Abstract: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.
    Type: Application
    Filed: October 12, 2007
    Publication date: February 5, 2009
    Inventors: Jay Schneider, Jenny Hsieh, Douglas Frantz, Steven L. McKnight, Joseph M. Ready
  • Publication number: 20080140447
    Abstract: Embodiments of the present invention relate to methods and apparatuses serving to provide assurance that healthcare providers will receive payment for services rendered. In one embodiment, a payment card (or other portable consumer device) provides an extended authorization hold period (for example up to 21 days). This hold period allows the healthcare provider to request authorization for payment from the patient's credit, debit, FSA, HRA, or HSA payment card, submit the insurance claim, and then upon receipt of a health insurance carrier's Explanation of Benefits (EOB) within the hold period, submit for settlement only that amount actually due from the patient. In accordance with an alternative embodiment, pending receipt of the EOB from the insurer, the healthcare provider flags a transaction in a point-of-sale (POS) terminal device or server for storage and delayed submittal over an electronic payment network.
    Type: Application
    Filed: June 8, 2007
    Publication date: June 12, 2008
    Inventors: Stacy Pourfallah, Janet Pruitt, Douglas Frantz, Roxanna Kayoumi
  • Publication number: 20060183897
    Abstract: Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Application
    Filed: March 12, 2004
    Publication date: August 17, 2006
    Inventors: Prasun Chakravarty, Michael Fisher, Brenda Palucki, Min Park, William Parsons, Bishan Zhou, James Carey, Douglas Frantz, Michael Kress, Damian Weaver
  • Publication number: 20050119261
    Abstract: Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
    Type: Application
    Filed: March 12, 2004
    Publication date: June 2, 2005
    Inventors: Prasun Chakravarty, Michael Fisher, Jeffrey Fisher, Brenda Palucki, Min Park, William Parsons, Bishan Zhou, James Carey, Douglas Frantz, Michael Kress, Damian Weaver